RxDoctor Payments Data

Alexander Landfield, MD

Neurology · Winchester, KYNPI 1447451463

Payments from drug & device makers

$6,912in general payments, 2019–2025

Across 525 payments — averaging $13.17 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • Pfizer$1K
  • Novartis$637
  • Lilly USA, LLC$432
  • Teva Pharmaceuticals USA, Inc.$411
  • Biohaven Pharmaceutical Holding Company Ltd.$346
  • plus $2K from 32 others

What the payments were for

  • Food & beverage$6,912100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$6,912 in reported general payments places this provider in the 60th percentile of 210 neurology providers in Kentucky.

See all neurology providers in Kentucky

Medicare billing

Part B allowed, 2024
$127,613
Medicare patients
447
Services billed
5,410

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
PrivigenImmun Glob G(Igg)/Pro/Iga 0-5026$514,102
Kesimpta PenOfatumumab31$298,803
Nurtec OdtRimegepant Sulfate137$215,994
QuliptaAtogepant129$158,810
Emgality PenGalcanezumab-Gnlm174$150,455
Aimovig AutoinjectorErenumab-Aooe132$112,834
EliquisApixaban75$66,057
UbrelvyUbrogepant49$56,293
TrudhesaDihydroergotamine Mesylate12$48,665
Emgality SyringeGalcanezumab-Gnlm50$43,774
Teriflunomide13$29,550
BriviactBrivaracetam17$27,589
NuedextaDextromethorphan Hbr/Quinidine16$22,852
Memantine Hcl793$18,950
LyricaPregabalin16$17,604

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerNurtec Odt, Eliquis, Lyrica, Dilantin$1,483$303,738242 claims
AbbVieQulipta, Ubrelvy$1,766$215,104178 claims
Impel Pharmaceuticals Inc.Trudhesa$131$48,66512 claims
UCB, Inc.Briviact$122$27,58917 claims
Avanir Pharmaceuticals, Inc.Nuedexta$34$22,85216 claims
AstraZenecaBrilinta$47$6,37520 claims
Amneal Pharmaceuticals LLCPyridostigmine Bromide$18$4,40250 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 210 neurology providers in Kentucky.

Other neurology in Winchester

See the full list for Kentucky

Where these figures come from

Is this you, or does something look wrong? →